List of pharmaceutical compound number prefixes
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names , and for which the effort to generate nonproprietary names may not be warranted, see article on drug nomenclature . Instead, these compounds are usually given a number for internal reference at the company. To distinguish the numbered compounds from different companies (or academic laboratories), each compound number is prefixed with a letter code indicating the company that developed the compound, that claims intellectual property on that compound etc. The letter code is conceived by companies themselves who should be interested in creating a unique code. Three main methods are found for prefixing the numeric identifier – with a space (gap),[ 1] [ 2] [ 3] [ 4]
For example, ABT-199 is a compound developed at Abbott Laboratories , and this name has been used in early publications of research results. Later the compound was assigned the international nonproprietary name (INN) venetoclax . Similarly, other compounds may be given a USAN or BAN for example. Finally, the compound may be given a trade name for example for marketing purposes.
A long list of code designations with corresponding trade names can be found in Appendix IV of the USP Dictionary, see article on drug nomenclature .
Note that this convention of composing compound identifiers from a company identifier followed by a number is not always followed. For example, the letter code may reflect a therapeutic/disease area or an internal project name. A randomly picked example is SC for spinal cord injury.[ 5]
A to F
ARQ – ArQule
ARRY Array BioPharma
ASP – Astellas Pharma [ 9]
AT – Arecor Therapeutics [ 10]
ATB - Antibe Therapeutics
ATL – Antisense Therapeutics Limited, Australia
AVXS – AveXis , in May 2018 acquired by Novartis
AY – Ayerst , later Wyeth-Ayerst, ultimately acquired by Pfizer
AZD – AstraZeneca
BAN – BioArctic Neuroscience AB, Sweden
BAY – Bayer AG
BB – Bluebird Bio
BCX – Laboratoires Biocodex
BI - Boehringer Ingelheim
BIIB – Biogen
BMS – Bristol-Myers Squibb
BMY – Bristol-Myers Co., merging in 1989 into Bristol-Myers Squibb
BRL – Beecham Research Labs, merged with SmithKline into SmithKline Beecham which merged into GlaxoSmithKline
BTC – The Boots Company plc
C – Laboratoires Cassenne
CAM – Cambridge Antibody Technology , acquired by AstraZeneca
CAS – Cassella Farbwerke Mainkur Aktiengesellschaft , later Hoechst, later Sanofi
CAT – Cannasat Therapeutics Inc., renamed 2010 Cynapsus Therapeutics
CAT – Cambridge Antibody Technology , acquired by AstraZeneca
CC – Celgene
CE – Pfizer
CGS – Ciba Geigy
CP – Pfizer. CP refers to C. P. Pharmaceuticals , a subsidiary of Pfizer [ 11]
CSL – CSL Limited , an Australian biopharmaceutical company
CVX – CovX , acquired by Pfizer in 2008
CYT – Cytopia of Australia, acquired by YM Biosciences , subsequently by Gilead Sciences [ 12]
D – Draco division of Astra AB , now AstraZeneca
DMP – DuPont Merck Pharmaceuticals, a joint venture between DuPont and Merck ; became DuPont Pharmaceuticals in 1998
DPC – DuPont Pharmaceuticals , acquired by Bristol-Myers Squibb in 2001
DS - Daiichi Sankyo
DX – Dyax
EAG – Eagle Pharmacy , a United States pharmaceutical compounding company [ 13]
EIDD – Emory Institute for Drug Development
EMD – Merck KGaA (E. Merck), Darmstadt, Germany (refers to laboratory founder Emanuel Merck in Darmstadt )
ETC – Esperion Therapeutics , acquired by Pfizer in 2003, independent again since 2008
F – Forest Labs , acquired by Actavis
FCE – Farmitalia-Carlo Erba , later Pharmacia AB, later Pharmacia & Upjohn, acquired by Pfizer
FF – Fujifilm
FG – FibroGen
FK – Fermentek
FPI – Fusion Pharmaceuticals
FS – F-star
G to L
G – J. R. Geigy AG, ultimately merged into Novartis
G – Genta Inc.
GDC – Genentech Likely Genentech Development Candidate [ 14] [ 15]
GEH – GE Healthcare
GNE – Genentech internal reference number, company pipeline uses GDC- prefixes [ 14] [ 16]
GP – Geigy, merged with CIBA in 1971 to become Ciba-Geigy , now Novartis
GR – GlaxoSmithKline
GS – Gilead Sciences
GS – Gesynta Pharma [ 17]
GSK – GlaxoSmithKline
H – Hässle division of Astra AB , now AstraZeneca
HCV – ViroPharma
HOE – Hoechst AG
ICI – Imperial Chemical Industries , acquired by AkzoNobel and merged into Zeneca Group by the merger of the pharmaceutical operations. Now part of AstraZeneca
IDN – Idun Pharmaceuticals , acquired by Pfizer
ILY – Ilypsa , acquired by Amgen in 2007
INNO – CytRx
ION – Ionis
IPI – Infinity Pharmaceuticals , Inc
ISIS – Isis Pharmaceuticals (renamed Ionis Pharmaceuticals in 2015)
JNJ – Johnson & Johnson
KOS – Kosan Biosciences
KPT – Karyopharm Therapeutics
KU – KuDOS Pharmaceuticals
KW – Kyowa Hakko
L – Labaz Group , acquired by Elf Aquitaine in 1973 to form Sanofi
LU – Lundbeck
LY – Eli Lilly
M to S
MBX - MBX Biosciences [ 18]
MCN – McNeil Laboratories , now part of Johnson & Johnson
MDCO – The Medicines Company
MDL – Merrell Dow Pharmaceuticals
MEDI – MedImmune , acquired by AstraZeneca [ 19]
MEM – Memory Pharmaceuticals
MRT - Monte Rosa Therapeutics [ 20]
MGX – Victory Pharma
MK – Merck & Co. (Merck Sharp & Dohme)
MLN – Millennium Pharmaceuticals
MT – Micromet , acquired by Amgen in 2012
NBI – Neurocrine Biosciences [ 21]
NC – Nycomed
NC – Nippon Chemiphar
NCX – NicOx
NG – Neurogen Corp.
NI – Neurimmune
NKTR – Nektar Therapeutics
NVS – Novartis
OCT – Octant Bio
OGX – OncoGenex
OPC – Otsuka Pharmaceutical Co.
OSI – OSI Pharmaceuticals
PD – Parke-Davis , now Pfizer
PF – Pfizer
PHA – Pharmacia , now Pfizer
PNU – Pharmacia & Upjohn , now Pfizer
PT – Pearl Therapeutics , now part of AstraZeneca
PTI – Proteostasis Therapeutics Inc
R – Janssen Pharmaceutica , now part of Johnson & Johnson (Janssen began as Belgian and Dutch distributor for products of Gedeon Richter Plc. )
RDEA – Ardea Biosciences acquired by AstraZeneca
RDX – Ardelyx
RXC - Redx Pharma
REGN – Regeneron Pharmaceuticals [ 2]
RLY – Relypsa
RMI – Richardson-Merrell
RO – Hoffmann–La Roche
RP – ReceptorPharma
RPC – Receptos, now Celgene
RTI– Research Triangle Institute (mostly restricted to various phenyltropanes )
RU – Roussel Uclaf
RWJ – R.W. Johnson Pharmaceutical Research , now part of Johnson & Johnson
SAGE – Sage Therapeutics
SAN – Sandoz Pharmaceuticals , now Novartis
SB – SmithKline Beecham , now GlaxoSmithKline
SC – G.D. Searle , now Pfizer
SCH – Schering Corp., later Schering-Plough
SKF – Smith, Kline & French , later merged into GlaxoSmithKline
SLV – Solvay
SNS – Sunesis Pharmaceuticals [ 22]
SNS – Sensei Biotherapeutics [ 23]
SPD – Shire
SPI – Spectrum Pharmaceuticals
SU – CIBA Pharmaceutical Company (the Summit, NJ site)
SU – SUGEN , now Pfizer
T to Z
References
^ "ArQule clinical pipeline" . Retrieved 2016-09-16 .^ a b "Regeneron PCSK9 Antibody REGN727" . Archived from the original on 2012-04-16. Retrieved 2012-04-17 .^ a b "Exelixis HSP90 inhibitor XL888" . Archived from the original on 2016-09-18. Retrieved 2016-09-16 .^ a b "AbbVie pipeline, using ABBV- as prefix" . Retrieved 2016-09-16 .^ "SC0806 clinical trial" . Retrieved 2018-07-26 .^ a b "AbbVie spun out of Abbott" . Chicago Tribune . Retrieved 2016-09-15 .^ "ADL5747" . Retrieved 2008-03-19 .[dead link ] ^ "Amgen goes 6-for-6 in Phase III" . 17 March 2014. Retrieved 2014-11-25 .^ "Overview of R&D Pipeline" (PDF) . Retrieved 2018-12-30 .^ "Our Portfolio" . Arecor Therapeutics . Retrieved 12 June 2023 .^ Drawbaugh, Tom Bergin (16 November 2015). "How Pfizer has shifted U.S. profits overseas for years" . Reuters . Retrieved 2019-11-06 . ^ "Edison outlook report on YM Biosciences" (PDF) . Retrieved 2016-09-19 .^ "Eagle Pharmacy – Pharmaceutical Compounding" . Retrieved 2016-04-26 .^ a b "Genentech Pipeline" . Retrieved 2016-09-29 .^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GDC-0152". Journal of Medicinal Chemistry . 59 (23): 10549– 10563. doi :10.1021/acs.jmedchem.6b01022 . PMID 27682507 . ^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GNE-272". Journal of Medicinal Chemistry . 59 (23): 10549– 10563. doi :10.1021/acs.jmedchem.6b01022 . PMID 27682507 . ^ "First patients dosed in phase II study of GS-248 in systemic sclerosis" . Bioworld Science . Clarivate Analytics. Retrieved 27 January 2021 .^ "MBX 2109" . Retrieved 2024-02-12 .^ "Pipeline – AstraZeneca" . Retrieved 2018-12-30 .^ "Monte Rosa MRT-6160" . Retrieved 2024-11-25 .^ "Neurocrine Vmat2 inhibitor NBI-98854" . Archived from the original on 2015-01-30. Retrieved 2016-09-13 .^ "Sunesis BTK inhibitor SNS-062" . Retrieved 2016-09-15 .^ "Sensei biotherapeutics anti VISTA" (Press release). October 2021. Retrieved 2021-11-29 .^ "Theravance Biopharma Pipeline" . Theravance pipeline background image . Retrieved 2024-02-12 .^ "Pipeline" . Terns Pharma pipeline . Retrieved 27 January 2021 .^ "TH-302 clinical trial" . Retrieved 2013-07-23 .^ "MM&M News" . 2008-12-18. Retrieved 2009-02-16 .^ "TransMolecular Product Pipeline" . Archived from the original on 2007-07-29. Retrieved 2007-11-18 .^ "Pipeline" . Totus Medicines Pipeline . Retrieved 25 August 2023 .^ "TOS-358 Clinical Trial" . Retrieved 25 August 2023 .^ "Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity" . Retrieved 25 August 2023 .^ "Taisho Press Release" . Retrieved 2008-01-07 .^ "UCL1684 at pubchem.gov" . Retrieved 2018-03-24 .
